Mawer Investment Management Ltd. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA)

Mawer Investment Management Ltd. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 0.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,903,326 shares of the company’s stock after selling 13,244 shares during the quarter. Moderna comprises 1.1% of Mawer Investment Management Ltd.’s investment portfolio, making the stock its 24th biggest holding. Mawer Investment Management Ltd. owned about 0.50% of Moderna worth $226,020,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after purchasing an additional 5,129,800 shares during the period. Wellington Management Group LLP boosted its position in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. Capital World Investors boosted its position in shares of Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after purchasing an additional 18,728 shares during the period. Norges Bank acquired a new stake in shares of Moderna in the 4th quarter valued at about $347,565,000. Finally, Bellevue Group AG boosted its position in shares of Moderna by 27.6% in the 4th quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock valued at $189,792,000 after purchasing an additional 413,095 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,158 shares of company stock valued at $13,239,712. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $76.61 on Tuesday. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a market capitalization of $29.45 billion, a P/E ratio of -4.89 and a beta of 1.68. The business has a 50 day moving average price of $98.47 and a 200 day moving average price of $112.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. During the same period last year, the business posted ($3.62) EPS. Sell-side analysts expect that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MRNA shares. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Royal Bank of Canada cut Moderna from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $125.00 to $90.00 in a research report on Monday, August 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $157.00 price objective (down from $214.00) on shares of Moderna in a research report on Friday, August 2nd. Finally, The Goldman Sachs Group decreased their price objective on Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Ten research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $123.79.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.